Fatal venous thrombembolism complicating imatinib therapy in patient with metastatic gastrointestinal stromal tumor

Abstract

Imatinib, a tyrosine kinase inhibitor, is currently the therapy of choice for gastrointestinal stromal tumor (GIST). The toxic effects of imatinib treatment are usually mild, and serious adverse events are rare.

We report here the case of a patient with peritoneal metastases of GIST involing the pelvis treated by imatinib.